Psychedelics will soon be treating a mental health patient near you.
The quality and breadth of clinical data that has already emerged, coupled with ever-increasing regulatory and political acceptance – along with enormous need in the mental health space – mean that it is now only a matter of time before these compounds start to be authorized in multiple markets and conditions.
Read more from Psychedelics Today Director of Education, David Drapkin, in this article by The Pharma Letter.
Click here to read more.
The Pharma Letter – The psychedelic medicine renaissance: how could the route to market play out?
